Predictive and prognostic markers in neuro-oncology (Q33311133)

25 July 2017

1 reference

title

Predictive and prognostic markers in neuro-oncology (English)

1 reference

25 July 2017

author name string

Martin J van den Bent

series ordinal

1

1 reference

25 July 2017

Johan M Kros

series ordinal

2

1 reference

25 July 2017

language of work or name

1 reference

1 December 2007

1 reference

Journal of Neuropathology & Experimental Neurology

25 July 2017

published in

1 reference

25 July 2017

volume

66

1 reference

25 July 2017

issue

12

1 reference

25 July 2017

page(s)

1074-1081

1 reference

Central pathology review in clinical trials for patients with malignant glioma. A Report of Radiation Therapy Oncology Group 83-02.

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Molecular pathology and clinical characteristics of oligodendroglial neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

MGMT: its role in cancer aetiology and cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

O6-methylguanine-DNA methyltranspherase gene expression in gliomas by means of real-time quantitative RT-PCR and clinical response to nitrosoureas

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

MGMT methylation: a marker of response to temozolomide in low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

The natural history of EGFR and EGFRvIII in glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Prognostic stratification of patients with anaplastic gliomas according to genetic profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

EGFR tyrosine kinase domain mutations in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31815C39F1

10.1097/NEN.0B013E31815C39F1

21 January 2018

Identifiers

DOI

1 reference

25 July 2017

1 reference